Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer

by Vandana Singh, Benzinga Editor

July 6, 2021 10:23 AM | 1 min read |

Health Canada has approved Puma Biotechnology Inc's PBYI Nerlynx (neratinib) in combination with capecitabine for metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.
Knight Therapeutics Inc KHTRF has the exclusive right to commercialize Nerlynx in Canada.
Nerlynx is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2, and HER4.
Price Action: PBYI shares are down 2.49% at $8.60 during the market session on the last check Tuesday.

Posted In: Biotech News Penny Stocks Health Care Contracts Small Cap FDA General breast cancer Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.